KR20070085674A - 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 - Google Patents

약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 Download PDF

Info

Publication number
KR20070085674A
KR20070085674A KR1020077012489A KR20077012489A KR20070085674A KR 20070085674 A KR20070085674 A KR 20070085674A KR 1020077012489 A KR1020077012489 A KR 1020077012489A KR 20077012489 A KR20077012489 A KR 20077012489A KR 20070085674 A KR20070085674 A KR 20070085674A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
growth
vancomycin
antimicrobial agent
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077012489A
Other languages
English (en)
Korean (ko)
Inventor
마누 챠우드해리
Original Assignee
비너스 레머디스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비너스 레머디스 리미티드 filed Critical 비너스 레머디스 리미티드
Publication of KR20070085674A publication Critical patent/KR20070085674A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020077012489A 2005-02-14 2006-02-08 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 Ceased KR20070085674A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN308/DEL/2005 2005-02-14
IN308DE2005 2005-02-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020097006944A Division KR20090052893A (ko) 2005-02-14 2006-02-08 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법

Publications (1)

Publication Number Publication Date
KR20070085674A true KR20070085674A (ko) 2007-08-27

Family

ID=36337659

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077012489A Ceased KR20070085674A (ko) 2005-02-14 2006-02-08 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법
KR1020097006944A Withdrawn KR20090052893A (ko) 2005-02-14 2006-02-08 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097006944A Withdrawn KR20090052893A (ko) 2005-02-14 2006-02-08 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법

Country Status (15)

Country Link
US (2) US7960337B2 (cg-RX-API-DMAC7.html)
EP (1) EP1848413B1 (cg-RX-API-DMAC7.html)
JP (1) JP4918502B2 (cg-RX-API-DMAC7.html)
KR (2) KR20070085674A (cg-RX-API-DMAC7.html)
CN (1) CN101080221A (cg-RX-API-DMAC7.html)
AU (1) AU2006213441B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0607168A2 (cg-RX-API-DMAC7.html)
CA (1) CA2597812C (cg-RX-API-DMAC7.html)
ES (1) ES2482700T3 (cg-RX-API-DMAC7.html)
MX (1) MX2007009754A (cg-RX-API-DMAC7.html)
NZ (1) NZ555077A (cg-RX-API-DMAC7.html)
PT (1) PT1848413E (cg-RX-API-DMAC7.html)
UA (1) UA91208C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006085337A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200704393B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080227732A1 (en) * 2005-05-13 2008-09-18 Venus Remedies Limited Treatment and Control of Severe Infections Including Cystic Fibrosis
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
GB2459126A (en) * 2008-04-10 2009-10-14 Peter Wilson Antimicrobial agent
CA2768582C (en) * 2009-07-24 2017-02-14 University Of Tennessee Research Foundation Spectinamides as anti-tuberculosis agents
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
JP5913367B2 (ja) 2011-01-05 2016-04-27 ホスピーラ インコーポレイテッド バンコマイシンの噴霧乾燥
ITLO20110001A1 (it) * 2011-05-03 2012-11-04 Fisiopharma Srl Flaconi di vancomicina cloroidrata con stabilità migliorata
RU2491921C1 (ru) * 2012-07-11 2013-09-10 Общество с ограниченной ответственностью "Опытно-технологическая фирма "Этрис" Способ лечения мастита у коров в сухостойный период
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
WO2014151845A1 (en) 2013-03-15 2014-09-25 Scuderi Group, Inc. Split-cycle engines with direct injection
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
KR102329764B1 (ko) 2013-03-15 2021-11-23 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
BE1021242B1 (nl) * 2014-06-11 2015-09-08 Neogen N.V. Teicoplanine lyofilisaten
WO2016071495A1 (en) 2014-11-06 2016-05-12 Xellia Pharmaceuticals Aps Glycopeptide compositions
DK3416669T3 (da) * 2016-02-19 2025-08-18 Klaus Brandenburg Midler og metoder til behandling af bakterielle infektioner
MX388732B (es) 2016-05-09 2025-03-20 Xellia Pharmaceuticals Aps Formulaciones de antibioticos glicopeptidicos estabilizados
CN107661470A (zh) * 2016-08-29 2018-02-06 成都特兰辰亚生物科技有限公司 添加有萘夫西林钠治疗痢疾的组合物
WO2022031830A1 (en) * 2020-08-04 2022-02-10 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
US11433115B2 (en) 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN117899225A (zh) * 2024-01-19 2024-04-19 芮城绿曼生物药业有限公司 一种增强免疫力的兽用抗菌注射剂、制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775533A (en) 1987-02-24 1988-10-04 Erbamont, Inc. Reconstitution of dry fill cyclophosphamide
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
GB9500978D0 (en) 1995-01-19 1995-03-08 Smithkline Beecham Plc Pharmaceutical formulations
AU6698496A (en) 1995-07-17 1997-02-18 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Metal-containing ribonucleotide polypeptides
JP4142149B2 (ja) * 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
AU2001267011B2 (en) * 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
US7378408B2 (en) 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection

Also Published As

Publication number Publication date
EP1848413B1 (en) 2014-04-09
NZ555077A (en) 2010-03-26
ZA200704393B (en) 2008-09-25
UA91208C2 (ru) 2010-07-12
PT1848413E (pt) 2014-07-18
US8778873B2 (en) 2014-07-15
EP1848413A1 (en) 2007-10-31
JP4918502B2 (ja) 2012-04-18
ES2482700T3 (es) 2014-08-04
AU2006213441A1 (en) 2006-08-17
WO2006085337B1 (en) 2006-11-02
AU2006213441B2 (en) 2011-12-01
BRPI0607168A2 (pt) 2009-08-11
KR20090052893A (ko) 2009-05-26
CA2597812C (en) 2012-01-24
MX2007009754A (es) 2007-11-07
JP2008530082A (ja) 2008-08-07
US20110257079A1 (en) 2011-10-20
US7960337B2 (en) 2011-06-14
CN101080221A (zh) 2007-11-28
US20080188403A1 (en) 2008-08-07
CA2597812A1 (en) 2006-08-17
WO2006085337A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
US8778873B2 (en) Parenteral combination therapy for infective conditions with drug resistant bacterium
ES2994966T3 (en) Single doses of oritavancin for treating or preventing a bacterial infection
EP2062581B1 (en) The antibiotics composition comprising beta-lactam antibiotics and ionic chelating agents
KR100900208B1 (ko) 감염의 치료에 대해 토탈 솔루션을 제공하는 항생제 배합물
JP2008540515A (ja) 嚢胞性線維症を含む重症感染症の処置および管理
Fortner et al. Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions
CN121419770A (zh) 包含抗细菌剂的药物组合及其组合物
WO2013042140A2 (en) Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
ES2690725T3 (es) Composiciones que comprenden cefepima y tazobactam
RU2521391C2 (ru) Новые однократные единичные составы карбапенема и аминогликозида
KR20110095856A (ko) 아즈트레오남과 카르바페넴류인 메로페넴 및 에르타페넴의 상승작용적 조합
JP6552648B2 (ja) 抗菌組成物
WO2024079094A1 (en) Methods of treating staphylococcus aureus bacteremia infections
Pezzani Cefuroxime
Eichenwald Antimicrobial therapy in children

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20070601

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080908

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090202

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080908

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20090304

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20090202

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20100930

Appeal identifier: 2009101001975

Request date: 20090304

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090403

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20090403

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20090304

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20081203

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20080820

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
E801 Decision on dismissal of amendment
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20090415

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20090415

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20090403

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20081203

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080820

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090304

Effective date: 20100930

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20100930

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20090304

Decision date: 20100930

Appeal identifier: 2009101001975